Abstract
Inhaled corticosteroid (ICS) therapy is recommended for most children with asthma irrespective of severity. Although this risks growth suppression, the benefit/risk profile is considered favorable.1,2 The effects of ICS on growth have mainly been evaluated in placebo-controlled trials; other controls used include nedocromil, montelukast, and sodium cromoglicate. Given the established role of ICS in treating asthma, it would not be ethical to enroll patients with moderate-severe asthma into a study where they may be randomized to non-ICS therapy. Therefore, much of the data characterizing the growth-suppressive effects of ICS comes from children with mild-moderate asthma.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
